Literature DB >> 22037801

Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.

Frank Lieberman1, Victor Yazbeck, Anastasios Raptis, Raymond Felgar, Michael Boyiadzis.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22037801     DOI： 10.1007/s11060-011-0739-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  35 in total

Review 1.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

2.  Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

Authors:  S H K Oertel; E Verschuuren; P Reinke; K Zeidler; M Papp-Váry; N Babel; R U Trappe; S Jonas; M Hummel; I Anagnostopoulos; B Dörken; H B Riess
Journal:  Am J Transplant       Date:  2005-12       Impact factor: 8.086

Review 3.  Primary central nervous system lymphoma.

Authors:  Elizabeth R Gerstner; Tracy T Batchelor
Journal:  Arch Neurol       Date:  2010-03

4.  Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Authors:  Robert Cavaliere; Gina Petroni; Maria B Lopes; David Schiff
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

5.  Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation.

Authors:  Y Aisa; T Mori; T Nakazato; S Suzuki; N Suzuki; Y Ikeda; S Okamoto
Journal:  Transpl Infect Dis       Date:  2009-06-02       Impact factor: 2.228

6.  Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate.

Authors:  L B Nabors; C A Palmer; B A Julian; A M Przekwas; C E Kew
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

7.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

Authors:  Ola Landgren; Ethel S Gilbert; J Douglas Rizzo; Gérard Socié; Peter M Banks; Kathleen A Sobocinski; Mary M Horowitz; Elaine S Jaffe; Douglas W Kingma; Lois B Travis; Mary E Flowers; Paul J Martin; H Joachim Deeg; Rochelle E Curtis
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

8.  Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Authors:  Eric T Wong; Roy Tishler; Loretta Barron; Julian K Wu
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

9.  Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.

Authors:  Nancy D Doolittle; Kristoph Jahnke; Richard Belanger; Deborah A Ryan; Robert W Nance; Cynthia A Lacy; Rose Marie Tyson; Marianne Haluska; Nancy A Hedrick; Csanad Varallyay; Edward A Neuwelt
Journal:  Leuk Lymphoma       Date:  2007-09

10.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.

Authors:  Sylvain Choquet; Stephan Oertel; Veronique LeBlond; Hanno Riess; Nathalie Varoqueaux; Bernd Dörken; Ralf Trappe
Journal:  Ann Hematol       Date:  2007-05-24       Impact factor: 3.673
View more
  8 in total

Review 1.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

2.  Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression.

Authors:  Zhenyang Gu; Bo Cai; Lei Yuan; Honghua Li; Wenrong Huang; Yu Jing; Haiyan Zhu; Yu Zhao; Jian Bo; Quanshun Wang; Xiaoping Han; Li Yu; Chunji Gao
Journal:  Int J Clin Exp Med       Date:  2014-07-15

3.  Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.

Authors:  Hikaru Sakamoto; Hidehiro Itonaga; Jun Taguchi; Takeharu Kato; Yasushi Sawayama; Tomayoshi Hayashi; Shiro Baba; Masako Moriuchi; Koichi Ohshima; Shinichiro Yoshida; Yukiyoshi Moriuchi; Yasushi Miyazaki
Journal:  Leuk Res Rep       Date:  2019-04-22

4.  Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma.

Authors:  Daniel Thomas Ginat; Alixandra Purakal; Peter Pytel
Journal:  J Neurooncol       Date:  2015-09-04       Impact factor: 4.130

5.  Epstein-Barr virus-associated posttransplant lymphoproliferative disorder involving the central nervous system following autologous hematopoietic stem cell transplantation for neuroblastoma.

Authors:  Hitoshi Sano; Masanobu Fujimoto; Keisuke Okuno; Jun-Ichi Ueyama; Shuichi Takano; Kazuhiko Hayashi; Susumu Kanzaki
Journal:  Springerplus       Date:  2014-10-06

6.  A Rare Presentation of Isolated CNS Posttransplantation Lymphoproliferative Disorder.

Authors:  Jaime Morris; Casey Smith; Andrew Streicher; Allison Magnuson; Susan Newman; Robert Bertoli
Journal:  Case Rep Oncol Med       Date:  2017-01-02

Review 7.  Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes.

Authors:  Ayumi Fujimoto; Ritsuro Suzuki
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

8.  Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis Under Immunosuppression After Liver Transplantation.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Martin Werner Hümmert; Florian Wegner; Martin Stangel; Kurt-Wolfram Sühs; Thomas Skripuletz
Journal:  Front Neurol       Date:  2019-09-25       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.